Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | BHMT | Q93088 | 3/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11342528 | 0.98 | FFAR1 (0.41) | FFAR1CPT2TDP1TSHRBHMT | |
| SCHEMBL6353014 | 0.93 | BHMT (0.41) | FFAR1CPT2TDP1TSHRBHMT | |
| SCHEMBL6341309 | 0.85 | BHMT (0.44) | FFAR1CPT2TDP1TSHRBHMT | |
| SCHEMBL27312675 | 0.79 | FFAR1 (0.43) | FFAR1CPT2TDP1TSHRRECQL | |
| SCHEMBL6693300 | 0.79 | TDP1 (0.65) | FFAR1CPT2TDP1TSHRBHMT | |
| SCHEMBL27403262 | 0.79 | FFAR1 (0.43) | FFAR1CPT2TDP1TSHRRECQL | |
| SCHEMBL5830172 | 0.77 | TSHR (0.43) | FFAR1CPT2TDP1TSHRRECQL | |
| SCHEMBL6346089 | 0.76 | TDP1 (0.68) | FFAR1CPT2TDP1TSHRBHMT | |
| SCHEMBL3283751 | 0.76 | TSHR (0.46) | FFAR1CPT2TDP1TSHRRECQL | |
| SCHEMBL6711879 | 0.76 | FFAR1 (0.41) | FFAR1CPT2TDP1TSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005068418-A1 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, STS, CBS | FFAR1 257/4885CPT2 240/4885TDP1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.